Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.40
Bid: 51.10
Ask: 51.70
Change: 0.20 (0.39%)
Spread: 0.60 (1.174%)
Open: 52.60
High: 52.60
Low: 51.40
Prev. Close: 51.20
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shares soar as Oxford Nanopore makes its London debut

Thu, 30th Sep 2021 10:42

(Sharecast News) - Shares in Oxford Nanopore Technologies surged on Thursday after the British biotech made its £3.4bn debut on the London Stock Exchange.
The initial public offering was priced at 425p, giving the firm, a specialist in DNA sequencing, a market value of £3.4bn when conditional trading got underway on Thursday.

The shares immediately started to climb, however, reaching 570p within the first hour of trading. By 1030 BST they were trading at around 605p.

Oxford Nanopore, which has also developed technology that enables the sequencing of Covid-19 variants, issued approximately 82.4m new shares, raising gross proceeds of around £350m.

Existing shareholders, including the London-listed investor IP Group, sold a further 41m shares, giving the total offer size of around £524m.

IP Group, which provided seed capital when Oxford Nanopore was spun out of Oxford University in 2005, raised around £84m. Of that, £15m will be allocated to a buyback programme, with the rest invested into its portfolio. It retains a 10.3% stake in Oxford Nanopore.

Proceeds from the IPO will be used to fund future growth. Gordon Sanghera, Oxford Nanopore chief executive, said the company was "in the foothills of a long and exciting journey".

He continued: "We are living on the cusp of a genomic era. I believe that our unique technology will open up many new possibilities for positive impact, both through enabling new discoveries in scientific research and through more accessible, faster [and] richer biological insights.

"We are delighted by the positive response we have received from investors. Our focus remains on continuing to innovate, grow, and working towards our goal of enabling the analysis of anything, by anyone, anywhere."

Unconditional trading in Oxford Nanopore is expected to start on Tuesday 5 October.

As at 1030 BST, shares in IP Group were ahead 3% at 140.2p.
More News
15 Nov 2021 14:15

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

Read more
11 Nov 2021 14:57

IN BRIEF: Ceres Power strikes deal with IP Group investee RFC

IN BRIEF: Ceres Power strikes deal with IP Group investee RFC

Read more
11 Nov 2021 09:18

IP Group portfolio company inks joint development agreement with Ceres Power

(Sharecast News) - Intellectual property company IP Group said on Thursday that portfolio company RFC Power, a long-duration energy storage company, had signed a joint development agreement with fuel cell technology firm Ceres Power.

Read more
29 Oct 2021 14:36

IN BRIEF: IP Group investee Hinge Health valued at over USD6 billion

IN BRIEF: IP Group investee Hinge Health valued at over USD6 billion

Read more
25 Oct 2021 16:10

IN BRIEF: IP Group books GBP27.5 million fair value gain

IN BRIEF: IP Group books GBP27.5 million fair value gain

Read more
25 Oct 2021 08:42

IP Group records £27.5m value gain after recent funding round

(Sharecast News) - Intellectual property-based business developer IP Group said on Monday that, following the completion of a funding round by a portfolio company in its top 20 most valuable holdings, it recorded a net realised and unrealised fair value gain of about £27.5m, or 2.6p per share.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
12 Oct 2021 14:40

IN BRIEF: Outgoing IP Group CEO Alan Aubrey buys 40,000 shares

IN BRIEF: Outgoing IP Group CEO Alan Aubrey buys 40,000 shares

Read more
6 Oct 2021 12:11

LONDON MARKET MIDDAY: Shares fall as gas prices fuel inflation fear

LONDON MARKET MIDDAY: Shares fall as gas prices fuel inflation fear

Read more
6 Oct 2021 09:26

IP Group CEO, CIO step down after Oxford Nanopore IPO

(Sharecast News) - IP Group said on Wednesday that chief executive Alan Aubrey and chief investment officer Mike Townend are retiring and stepping down from the board with immediate effect following the successful flotation of its largest holding, Oxford Nanopore Technologies.

Read more
6 Oct 2021 09:18

TOP NEWS: Oxford Nanopore IPO prompts change at top at IP Group

TOP NEWS: Oxford Nanopore IPO prompts change at top at IP Group

Read more
30 Sep 2021 12:11

LONDON MARKET MIDDAY: Stocks mixed; Oxford Nanopore soars on debut

LONDON MARKET MIDDAY: Stocks mixed; Oxford Nanopore soars on debut

Read more
30 Sep 2021 10:47

UPDATE: Oxford Nanopore nears GBP5 billion value in London debut

UPDATE: Oxford Nanopore nears GBP5 billion value in London debut

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.